EVENTS
Searching biomarkers for bladder cancer: linking -omics in body fluids
27/08/2010 9:00 am
- Speaker: Marta Sánchez-Carbayo - Tumor Markers Group - Spanish National Cancer Research Center (CNIO) - Madrid, Spain
- Language: English
- Location: CRP-Santé - Val Fleuri - Strassen
- Contact: andre.steinmetz@crp-sante.lu
Searching biomarkers for bladder cancer: linking -omics in body fluids - Bladder cancer is a disease driven by the multistep accumulation of genetic and epigenetic changes, among others. These molecular alterations may result in uncontrolled cellular proliferation, cell cycle deregulation, decrease in cell death or apoptosis, blockage of differentiation, invasion, and metastatic spread. The particular epigenetic, genetic and protein expression alterations that occur as part of the crosstalk between these pathways, will in great part determine the biological behavior of the tumor including its ability to grow, recur, progress and metastasize. The advent of high-throughput approaches is accelerating the discovery of the molecular alterations involved in tumorigenesis and bladder cancer progression. The use of epigenetic, genomic and proteomic technologies in tissue specimens are contributing to the identification of critical molecular event that could be considered potential targets for therapy and also be translated into cancer biomarkers. The potential for expanding our understanding of bladder carcinogenesis can be explored also in body fluids and linked to the molecular alterations found in matching tumor specimens. Furthermore, the application and optimization of high-throughput technologies in non-invasive specimens would contribute to translate epigenetic, genetic, genomic and proteomic alterations characteristic of bladder tumors into potential biomarkers that could be applied to the clinics. Several ongoing high-throughput strategies being developed and applied in our laboratory will be discussed for the identification of biomarkers that may aid for bladder cancer diagnosis, clinical outcome prognosis and prediction of therapeutic response to current treatments applied in clinical practice.